Drugs / PRT2527
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05665530 | Sep 2023 → Jun 2025 | Richter transformation, T-cell non-Hodgkin lymphoma, acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma +5 | Prelude Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05159518 | Feb 2022 → Dec 2023 | castration-resistant prostate carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, sarcoma | Prelude Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2024-12-11 | Prelude Therapeutics | Results Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies preludetx.com ↗
PRT2527 monotherapy and in combination with zanubrutinib demonstrated an acceptable safety profile with evidence of preliminary activity in patients with relapsed/refractory lymphoid malignancies, including patients who received prior CAR-T therapy. |
| 2024-04-09 | Prelude Therapeutics | Results Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting preludetx.com ↗
Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition |
| 2023-10-14 | Prelude Therapeutics | Results Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference preludetx.com ↗
This additional data from our solid tumor trial investigating our potent and selective CDK9 inhibitor, PRT2527, continues to support a best-in-class safety and target engagement profile for the molecule. |
| 2023-04-11 | Prelude Therapeutics | Results Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference preludetx.com ↗ |
| 2022-03-09 | Prelude Therapeutics | Results Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting preludetx.com ↗
Collectively, the data demonstrate that PRT2527 had potent antitumor activity in multiple models of castration-sensitive and castration-resistant prostate cancer, inhibited Myc transcriptional activity and reduced tumor stem-like cells. |
| 2021-11-08 | Prelude Therapeutics | Regulatory Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor preludetx.com ↗ |
| 2021-10-07 | Prelude Therapeutics | Results Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics preludetx.com ↗
CDK9 inhibitor PRT2527 demonstrates strong efficacy in hematological malignancies and solid tumor models with MYC dysregulation in preclinical studies |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRT2527 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05159518 ↗ |
| Action | Inhibit | “a CDK9 inhibitor” NCT05159518 ↗ |
| Route | Intravenous | “PRT2527 will be administered by intravenous infusion” NCT05159518 ↗ |
| Target | CDK9 | “a CDK9 inhibitor” NCT05159518 ↗ |